Saint Petersburg State University
Question
Asked 16th Sep, 2022
Is it correct to apply broken-line regression model to find the optimum level of a dose of medicine to a data set as followed?
The problem is in the second treatment group we had a higher value. In such cases what are the other applicable statistical methods to find the optimum level.
Most recent answer
Kasun Tharaka , я рад, если мой ответ был полезен Вам. С уважением
1 Recommendation
Popular answers (1)
Saint Petersburg State University
Регрессия по 4 точкам? Если Вам необходимо найти оптимальную дозу лекарства, то сначала, на мой взгляд, стоит убедится в том, есть ли у этого лекарства эффективность большая, чем у плацебо. Мне, к сожалению, не совсем понятно, в контрольной группе пациенты принимали плацебо или нет. Необходимо знать число пациентов и дисперсии в группах, чтобы дать ответ, есть ли неслучайные отличия или нет. С Уважением.
3 Recommendations
All Answers (9)
Statistical Consulting Services Inc
I assume that these are means. What is the number of observations for each dose? If the sample size is not sufficiently large, then having a non-monotone response is not surprising. Even with large sample sizes, an "umbrella" may not be shocking, depending on the disease or the treatment. Receptors can be "saturated", but this is may be "noise". How is "best" defined? If this is efficacy, safety must be incorporated, in which case T1 may be "best", assuming safety response is monotone and lower doses are safer, and T1 has adequate response
2 Recommendations
Saint Petersburg State University
Регрессия по 4 точкам? Если Вам необходимо найти оптимальную дозу лекарства, то сначала, на мой взгляд, стоит убедится в том, есть ли у этого лекарства эффективность большая, чем у плацебо. Мне, к сожалению, не совсем понятно, в контрольной группе пациенты принимали плацебо или нет. Необходимо знать число пациентов и дисперсии в группах, чтобы дать ответ, есть ли неслучайные отличия или нет. С Уважением.
3 Recommendations
Jeju National University
David R Bristol Thank you for the answer. Yes. these are means. The number of observations for each treatment is 36. Actually, this is related to a feeding trial of shrimps. We have incorporated an ingredient in different levels into the feed of shrimp. This data are 'weight gain' of the shrimp in different treatments where we consider as the effect of the ingredient. We wanted to find the optimum level of the ingredient. But, I am confused with broken line regression just because the weight gain value of T1 has raised.
Saint Petersburg State University
Кроме числа креветок, необходимо знать дисперсии в группах, чтобы дать ответ, есть ли неслучайные отклонения или нет.
С Уважением.
1 Recommendation
Saint Petersburg State University
Уважаемый Kasun Tharaka Средние во всех опытных группах Т1, Т2, Т3 и Т4 статистически не различаются, но они значимо выше среднего контрольной группы. Получается, прибавка в весе есть, но по Вашим данным невозможно определить, какой из типов кормления Т1, Т2, Т3 или Т4 лучше. Возможно, даже наилучшим будет меньшее количество ингредиента, чем в группе Т1.
1 Recommendation
Jeju National University
Daniil ( Даниил ) Александрович Fedorov ( Федоров ) Большое спасибо за ответ!
Saint Petersburg State University
Kasun Tharaka , я рад, если мой ответ был полезен Вам. С уважением
1 Recommendation
Similar questions and discussions
Medical Research Archive and European Society of Medicine - Beware of Predatory Journals
Muhammad Haseeb
Hello RG Community,
I recently received an email from "Oncology Editorial Committee" of "Medical Research Archives".
Dear Dr. Muhammad Haseeb,
I wanted to get in touch with you about your liver cancer work. I enjoyed your article "[Redacted]" and was wondering what further research you have done on this topic. This year I am helping to create a special theme issue titled New Perspectives on Liver Cancer which will be published in the official journal of the European Society of Medicine. Your work could be a valuable addition to the theme issue and I hope you would be willing to discuss the possibility of preparing an article.
Is this something you might consider?
Best Regards,
Section editor
Oncology Editorial Committee
Medical Research Archives
European Society of Medicine
ISSN: 2375-1924
NLM (PubMed) ID: 101668511
It seems a predatory journal and some other researchers have found the same.
For Example:
Polite invitation to submit article: Predatory journal's new strategy - PMC (nih.gov)
European Society of Medicine solicitations | OIT | Brown University
Beware of these kinds of emails! | ResearchGate
UG/UMCG authors falling prey to fraudulent/predatory publishing practices | Open access | University of Groningen Library | University of Groningen (rug.nl)
The journal name "Medical Research Archives" confuses with its Look Alike, Sound Alike (LASA) journal "Archives of Medical Research", a ScienceDirect journal.
The dark side of antivirals
SMJ Mortazavi
Heyer et al. in their recent paper "Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection" published in Cell Reports Medicine have reported that remdesivir treatment can result in rapid fixation of newly acquired mutations. They have also noted that "Treatment-associated evolutionary bottlenecks promote emergence of novel variants". It's great to see that the validity of our early hypothesis has been confirmed by other researchers. We strongly believe that the "Remdesivir-induced emergence of SARS-CoV2 variants" is the dark side of the antivirals such as remdesivir that needes further investigation.
Mehdizadeh AR, J Bevelacqua J, Mortazavi SAR, S Welsh J, Mortazavi SMJ. How Antivirals Might be Linked to the Emergence of New Variants of SARS-CoV-2. J Biomed Phys Eng. 2021 Apr 1;11(2):123-124. doi: 10.31661/jbpe.v0i0.2101-1275. PMID: 33937119; PMCID: PMC8064135.
https://lnkd.in/d4U2UTK
Heyer, A. et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Reports Medicine 3, 100735 (2022). https://doi.org:https://lnkd.in/e7NQWhP7
Heyer, A. et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Reports Medicine 3, 100735 (2022). https://doi.org:https://lnkd.in/e7NQWhP7
Related Publications
The purpose underlying the main aim of the present study is to apply the competing risks of survival analysis upon the comprehensive insurance practices, which-in itself-is a non-life insurance type. To serve for the purpose, a detailed insurance data set comprising seven explanatory variables that encompass 98,667 observations was taken into consi...
Dataset for the tutorial: "Regression models, fantastic beasts and where to find them: An ecologist's perspective"